Neuropsychological and neurophysiological characterization of mild cognitive impairment and Alzheimer's disease in Down syndrome.

Alzheimer's disease Down syndrome Magnetoencephalographic source analysis Magnetoencephalography Mild cognitive impairment Neuropsychological performance

Journal

Neurobiology of aging
ISSN: 1558-1497
Titre abrégé: Neurobiol Aging
Pays: United States
ID NLM: 8100437

Informations de publication

Date de publication:
12 2019
Historique:
received: 08 04 2019
revised: 03 07 2019
accepted: 30 07 2019
pubmed: 14 9 2019
medline: 7 8 2020
entrez: 14 9 2019
Statut: ppublish

Résumé

Down syndrome (DS) has been considered a unique model for the investigation of Alzheimer's disease (AD) but intermediate stages in the continuum are poorly defined. Considering this, we investigated the neurophysiological (i.e., magnetoencephalography [MEG]) and neuropsychological patterns of mild cognitive impairment (MCI) and AD in middle-aged adults with DS. The sample was composed of four groups: Control-DS (n = 14, mean age 44.64 ± 3.30 years), MCI-DS (n = 14, 51.64 ± 3.95 years), AD-DS (n = 13, 53.54 ± 6.58 years), and Control-no-DS (healthy controls, n = 14, 45.21 ± 4.39 years). DS individuals were studied with neuropsychological tests and MEG, whereas the Control-no-DS group completed only the MEG session. Our results showed that the AD-DS group exhibited a significantly poorer performance as compared with the Control-DS group in all tests. Furthermore, this effect was crucially evident in AD-DS individuals when compared with the MCI-DS group in verbal and working memory abilities. In the neurophysiological domain, the Control-DS group showed a widespread increase of theta activity when compared with the Control-no-DS group. With disease progression, this increased theta was substituted by an augmented delta, accompanied with a reduction of alpha activity. Such spectral pattern-specifically observed in occipital, posterior temporal, cuneus, and precuneus regions-correlated with the performance in cognitive tests. This is the first MEG study in the field incorporating both neuropsychological and neurophysiological information, and demonstrating that this combination of markers is sensitive enough to characterize different stages along the AD continuum in DS.

Identifiants

pubmed: 31518951
pii: S0197-4580(19)30277-5
doi: 10.1016/j.neurobiolaging.2019.07.017
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

70-79

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Javier García-Alba (J)

Research and Psychology in Education Department, Complutense University of Madrid, Madrid, Spain; Center for Biomedical Technology, Laboratory of Cognitive and Computational Neuroscience, Technical University of Madrid, Campus Montegancedo, Madrid, Spain. Electronic address: jgalba@edu.ucm.es.

Federico Ramírez-Toraño (F)

Center for Biomedical Technology, Laboratory of Cognitive and Computational Neuroscience, Technical University of Madrid, Campus Montegancedo, Madrid, Spain; Department of Experimental Psychology, Complutense University of Madrid, Campus de Somosaguas, Pozuelo de Alarcón, Madrid, Spain.

Susanna Esteba-Castillo (S)

Specialized Department in Mental Health and Intellectual Disability, Parc Hospitalari Martí i Julià - Institut d'Assistència Sanitària, Institut d'Assistència Sanitària (IAS), Girona, Spain; Neurodevelopment group [Girona Biomedical Research Institute]-IDIBGI, Institute of Health Assistance (IAS), Parc Hospitalari Martí i Julià, Girona, Spain.

Ricardo Bruña (R)

Center for Biomedical Technology, Laboratory of Cognitive and Computational Neuroscience, Technical University of Madrid, Campus Montegancedo, Madrid, Spain; Department of Experimental Psychology, Complutense University of Madrid, Campus de Somosaguas, Pozuelo de Alarcón, Madrid, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain.

Fernando Moldenhauer (F)

Internal Medicine Department, Adult Down Syndrome Unit, La Princesa University Hospital, Health Research Institute, Madrid, Spain.

Ramón Novell (R)

Specialized Department in Mental Health and Intellectual Disability, Parc Hospitalari Martí i Julià - Institut d'Assistència Sanitària, Institut d'Assistència Sanitària (IAS), Girona, Spain; Neurodevelopment group [Girona Biomedical Research Institute]-IDIBGI, Institute of Health Assistance (IAS), Parc Hospitalari Martí i Julià, Girona, Spain.

Verónica Romero-Medina (V)

Center for Biomedical Technology, Laboratory of Cognitive and Computational Neuroscience, Technical University of Madrid, Campus Montegancedo, Madrid, Spain.

Fernando Maestú (F)

Center for Biomedical Technology, Laboratory of Cognitive and Computational Neuroscience, Technical University of Madrid, Campus Montegancedo, Madrid, Spain; Department of Experimental Psychology, Complutense University of Madrid, Campus de Somosaguas, Pozuelo de Alarcón, Madrid, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain.

Alberto Fernández (A)

Center for Biomedical Technology, Laboratory of Cognitive and Computational Neuroscience, Technical University of Madrid, Campus Montegancedo, Madrid, Spain; Department of Legal Medicine, Psychiatry and Pathology, Complutense University of Madrid, Spain, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH